Merck & Co. Stock News

Merck (MRK) is close to acquiring Cidara Therapeutics (CDTX) in a deal potentially exceeding $3.3 billion, with announcement expected soon. CDTX shares surged 85% on news of the potential acquisition, which may include upfront cash and milestone-based payouts.

Merck is closing in on a deal to buy Cidara Therapeutics in a deal valuing the biotechnology company at a premium to its $3.3 billion market capitalization, the Financial Times reported on Thursday.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies Global Healthcare Conference in London.

Pfizer and Merck are two of the largest drug companies on the planet. Both companies are dealing with upcoming patent expirations.

These two tried-and-tested healthcare giants have compelling portfolios and pipelines. Pfizer is moving on from the pandemic era, and a stream of acquisitions has bolstered its pipeline.

The overall market may be up solidly this year, but some individual shares still look like bargains. Merck's evolving core franchise and new launches should help mitigate the risks facing its business.

Merck & Co., Inc. ( MRK ) Shareholder/Analyst Call November 9, 2025 7:01 PM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Dean Li - Executive VP & President of Merck Research Laboratories Joerg Koglin - Senior VP & Head of General Medicine - Global Clinical Development Jannie Oosthuizen - Senior VP & President Merck U.S. Human Health Conference Call Participan...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 CORALreef HeFH Trial.